Sign In
Buy STTK
$4.75
-0.120 (-2.46%)
At Close: Jun 03, 2026
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
06:00am, Friday, 14'th Jun 2024
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overa
AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion pro
- Conference call and webcast to be held June 14, 2024 at 7:30 a.m. ET featuring lead investigator - AUSTIN, TX and DURHAM, NC, June 06, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq
After Plunging -19.89% in 4 Weeks, Here's Why the Trend Might Reverse for Shattuck Labs (STTK)
10:36am, Tuesday, 21'st May 2024
Shattuck Labs (STTK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estim
– Observed encouraging complete response (CR) rates as of the February 1, 2024, data cutoff in previously untreated HR-MDS and TP53m AML patients; successfully bridged responding TP53m AML patients
What Makes Shattuck Labs (STTK) a New Buy Stock
01:01pm, Tuesday, 07'th May 2024
Shattuck Labs (STTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does Shattuck Labs (STTK) Have the Potential to Rally 34.17% as Wall Street Analysts Expect?
10:56am, Tuesday, 07'th May 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 34.2% in Shattuck Labs (STTK). While the effectiveness of this highly sought-after metric is questionable, the
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
09:31am, Thursday, 02'nd May 2024
Shattuck Labs, Inc. (STTK) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.49 per share a year ago.
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
07:05am, Thursday, 02'nd May 2024
- Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at th
– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired res
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
07:00am, Monday, 01'st Apr 2024
AUSTIN, TX & DURHAM, NC, April 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pro
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D.
07:00am, Monday, 04'th Mar 2024
AUSTIN, TX and DURHAM, NC, March 04, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion pr
Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights
04:05pm, Thursday, 29'th Feb 2024
- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontlin
Shattuck Labs Announces Participation in Upcoming March Conferences
07:00am, Monday, 26'th Feb 2024
AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion p
Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
05:06am, Wednesday, 14'th Feb 2024
OSAKA, Japan , Feb. 14, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration
